DetoxificationNCT07579845
Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress
A study testing Humic and Fulvic Acid Dietary Supplement in people with Detoxification and Inflammation, run by OvationLab at 1 site in United States.
Trial summary
The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Detoxification, Inflammation, Biological Aging
- What is being tested?
- Humic and Fulvic Acid Dietary Supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 5 May 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult females or males age ≥ 40 years
- Ability to read and speak English
Who cannot join
- Current use of a dietary supplement containing fulvic or humic acid
- Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
- Known allergies to any ingredients in the product
- Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
- Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
- Participants unable to provide consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
OvationLab
Richmond, Virginia, 23220
Study Administration, (240) 232-2103, info@ovationlab.com
About this study
The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.
- Conditions
- Detoxification, Inflammation, Biological Aging
- Being tested
- Humic and Fulvic Acid Dietary Supplement
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Humic and Fulvic Acid Dietary SupplementDietary supplement
BioToxin Binder (CellCore Biosciences, Palm Beach Gardens, FL) - Humic and Fulvic Acid Dietary Supplement
| Study group | Role | What they receive |
|---|---|---|
| Humic and Fulvic Acid Dietary Supplement | Experimental | Not described Receives: Dietary Supplement: Humic and Fulvic Acid Dietary Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
TruDiagnostic - Epigenetic Testing
TruAge Test
Measured: Change in TruAge from baseline to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2026
- Study start5 May 2026
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DetoxificationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- OvationLab
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07579845
- Sponsor's protocol ID
- CC-001
- Status last verified
- May 2026
- First submitted
- 30 Apr 2026
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress
- ClinicalTrials.gov ID
- NCT07579845
- Acronym / sponsor ID
- CC-001
- Conditions
- Detoxification, Inflammation, Biological Aging
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- OvationLabResearch network
- Study start
- 5 May 2026 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 12 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Humic and Fulvic Acid Dietary Supplement | Experimental | Dietary Supplement: Humic and Fulvic Acid Dietary Supplement |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adult females or males age ≥ 40 years
- Ability to read and speak English
Key exclusion criteria (6 listed)
- Current use of a dietary supplement containing fulvic or humic acid
- Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
- Known allergies to any ingredients in the product
- Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
- Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Humic and Fulvic Acid Dietary SupplementBioToxin Binder (CellCore Biosciences, Palm Beach Gardens, FL) - Humic and Fulvic Acid Dietary Supplement | Dietary supplement | Humic and Fulvic Acid Dietary Supplement |
Primary outcome
TruDiagnostic - Epigenetic Testing
Time frame: Change in TruAge from baseline to 12 weeks
TruAge Test
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: No
Related trials for Detoxification
RecruitingPhase 2/3
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification
Recruiting
Prospective Human Study Evaluating Changes in Markers of Detoxification, Overall Physical and Mental Health, and Fatigue Following Supplementation With CellCore Protocols
Environmental Toxins, General Health
Not yet recruitingPhase 1/2
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
Opioid Use Disorder, Opioid Withdrawal
Recruiting
Greater Occipital Nerve Block for Migraine With Medication Overuse Headache
Migraine Disorders, Medication Overuse Headache
RecruitingObservational study
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
Opioid Withdrawal, Opioid Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Humic and Fulvic Acid Dietary Supplement in people with Detoxification and Inflammation, run by OvationLab at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Administrator ((240) 232-2103, info@ovationlab.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
TruDiagnostic - Epigenetic Testing (time frame: Change in TruAge from baseline to 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.